Climb Bio (NASDAQ:CLYM) Now Covered by Analysts at Oppenheimer
Oppenheimer began coverage on shares of Climb Bio (NASDAQ:CLYM – Free Report) in a report published on Friday morning, Marketbeat Ratings reports. The firm issued an outperform rating and a $10.00 price objective on the stock. Separately, BTIG Research started coverage on Climb Bio in a research note on Thursday, May 22nd. They set a […]
Oppenheimer began coverage on shares of Climb Bio (NASDAQ:CLYM – Free Report) in a report published on Friday morning, Marketbeat Ratings reports. The firm issued an outperform rating and a $10.00 price objective on the stock. Separately, BTIG Research started coverage on Climb Bio in a research note on Thursday, May 22nd. They set a […]
